Patients: A total of 9650 adult patients with established CV disease without CKD (56.7%), CKD only (13%), or both CV disease and CKD (27%) were randomized 1:1 to receive semaglutide tablets 14 mg (n=4825) or placebo (n=4825) once daily, both in addition to standard-of-care treatments for glycemic control and CV risk factors including blood pressure medication, lipid-lowering agents, and antiplatelet/anticoagulant therapy
Every patch is developed in the United States, manufactured in a cGMP-certified facility, and subject to rigorous third-party testing for pharmaceutical-grade purity, stability, and consistency
Any associated weight loss is framed as increased calorie expenditure and central nervous system appetite suppression, not hormonal signaling
These side effects happen because GLP-1s slow gastric emptying and change appetite signaling in the brain
(17(8)):e01712 doi:10.1213/XAA.0000000000001712